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Introduction
Telomerase is a ribonucleoprotein complex that maintains
chromosome stability and, ultimately, cell lifespan by telomere
maintenance (reviewed in Counter et al., 1992; Harley and
Villeponteau, 1995). The absence of telomerase is associated
with shortening of telomeres and aging of somatic cells. The
activity of this enzyme is normally downregulated in somatic
cells, whereas it is highly upregulated in cells that are actively
dividing, such as malignant cells, strongly suggesting a key
role in tumourigenesis (Greider, 1998; Shay and Bacchetti,
1997). Given the difference in telomerase expression between
normal and tumour cells, telomerase activity or telomerase
components could be potentially useful as novel diagnostic
markers for a wide range of cancers (reviewed by Hiyama and
Hiyama, 2003; Ulaner, 2004). Extensive characterization of
telomerase activity was made possible through the
development of the highly sensitive telomeric repeat
amplification protocol-polymerase chain reaction (TRAP-
PCR) assay (Kim et al., 1994), which was the first method
employed to estimate the abundance of telomerase in human
normal and cancerous tissues. Detection of high levels of
telomerase activity in tumour tissues usually suggests a less
favourable prognosis and predicts unfavourable outcomes and
shorter survival (Hiyama et al., 1995a; Hiyama et al., 1995b;
Langford et al., 1997). Hence, inclusion of telomerase activity
as a prognostic marker should be considered in future
validation studies.
The cloning of the catalytic subunit of telomerase gene
(hTERT) has allowed the evaluation of hTERT mRNA level
and its correlation with telomerase activity (Counter et al.,
1997; Lingner et al., 1997; Nakamura et al., 1997).
Importantly, these studies have revealed that these two
parameters were not always correlated (Counter et al., 1998;
Klapper et al., 2001; Rohde et al., 2000). This is reminiscent
of the existence of additional nontranscriptional mechanisms
involved in the regulation of telomerase activity. Indeed,
besides transcription, telomerase may be regulated at post-
transcriptional (alternative splicing) and post-translational
(phosphorylation) levels, and its intracellular localization may
also play an important role (Cong et al., 2002; Kilian et al.,
1997; Liu et al., 2001; Mergny et al., 2002). Furthermore, it
is now well-recognized that telomerase is endowed with
additional functions far from telomeres that are independent
of the telomere elongating activity measured by the TRAP
The involvement of telomerase in cellular immortalization
and senescence has often been assessed by means of
telomerase expression at the RNA level and quantification
of telomerase activity by the telomeric repeat amplification
protocol assay. However, these methods either neglected the
existence of various telomerase splice variants, or ignored
the nonconventional functions of telomerase independent of
its ability to elongate and maintain telomere length.
Immunodetection of telomerase is now being recognized as
a necessary approach to precisely elucidate its roles in
oncogenesis and senescence. A few antibodies directed
against the catalytic subunit of the human telomerase
(hTERT) are currently used but their specificity is not
always demonstrated. A survey of the literature showed
inconsistencies and led us to comparatively re-evaluate the
most frequently used antibodies. Surprisingly, mass
spectrometry, two-dimensional gel analysis and
immunofluorescent experiments revealed that the most
frequently used hTERT immunoprobe, a mouse
monoclonal antibody that was claimed to be directed
against an hTERT protein epitope, in fact recognizes
nucleolin rather than telomerase. Our findings have
interesting implications regarding the biology of nucleolin
and telomerase in the context of pathophysiological
investigations recently carried out.
Supplementary material available online at
http://jcs.biologists.org/cgi/content/full/119/13/2797/DC1
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assay (Dudognon et al., 2004; Fu et al., 1999; Stewart et al.,
2002).
Nowadays, the current knowledge on telomerase expression
and functions imposes a precise and reliable detection of
telomerase protein by immunological techniques. Antibodies
against epitope-tagged fusion hTERT proteins have been used
for the detection of ectopic expression of hTERT and
molecular applications in cell model systems (Etheridge et al.,
2002; Khurts et al., 2004; Santos et al., 2004; Seimiya et al.,
2000; Wong et al., 2002; Zhu et al., 2004). However, it cannot
be applied to fresh tissues or cells to study hTERT endogenous
expression and localization. An increasing number of reports
based on immunological methods establish telomerase as a
marker for tumour growth and progression. Unfortunately, to
date, only a few antibodies directed against telomerase epitopes
have been reported. However, difficulties in detecting the
enzyme have been mentioned, related to the low abundance of
the enzyme in cells (Frost et al., 2000; Wada et al., 2000) and
to the lack of specificity of these antibodies, all features which
are generally well-recognized although not actually discussed
in the publications.
An overall investigation on the epitope specificity of
commonly used anti-hTERT antibodies has revealed
unexpected but interesting biological features of several of
these reagents. The most salient points are herein reported. A
new mouse monoclonal antibody (Novocastra, NCL-hTERT,
clone 44F12) has been widely used, based on the assumption
that this antibody correctly recognizes the protein peptide
against which it has been claimed to be developed (Brustmann,
2005; Dalerba et al., 2005; Domont et al., 2005; Dutu et al.,
2005; Elkak et al., 2005; Falchetti et al., 2003; Fullen et al.,
2005; Gulmann et al., 2005a; Kraemer et al., 2003; Lantuejoul
et al., 2005; Lantuejoul et al., 2004; Luzar et al., 2005a; Luzar
et al., 2005b; Maes et al., 2005; Sabah et al., 2004; Sato et al.,
2004; Smith et al., 2004; Uziel et al., 2005; Yan et al., 2004).
Using this antibody, we confirmed on western blots, as
previously shown, the labelling of a unique protein band in the
100 kDa area, which is generally thought consistent with the
estimated molecular weight of telomerase of 127 kDa (Wick
et al., 1999). Strikingly, control experiments using either
telomerase-negative or hTERT-overexpressing cells cast some
doubt on the nature of the protein recognized by this antibody.
Starting from these observations, a detailed re-evaluation of the
efficacy and specificity of this antibody was performed
comparatively with other commercially available anti-hTERT
antibodies.
Results
Expression of hTERT mRNA level in engineered human
cell lines
Different sets of cell lines were investigated for their relative
levels of hTERT mRNA expression (supplementary material
Fig. S2) using fluorescence real-time PCR. HeLa cells were
engineered to ectopically over-express either hTERT or
haemagglutinin (HA)-tagged hTERT. This latter subline allows
a precise evaluation of the specificity of any protein band
detected on western blots. NB4-LR1 acute promyelocytic
leukemia (APL) cells exhibited a high hTERT expression. This
expression was further increased by ectopic hTERT expression
in the NB4-LR1/hTERT cells. GM847 was described as a
telomerase-negative expressing cell line which used alternative
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lengthening of telomeres (ALT) mechanisms to maintain
telomere length (Bryan et al., 1995; Henson et al., 2002). In
this cell line, hTERT mRNA expression was nearly
undetectable. Ectopic hTERT mRNA in GM847 cells was
detectable, although it remained at a much lower level than in
any other ectopically hTERT-over-expressing cell lines tested.
hTERT protein expression in differentiating NB4-LR1
APL cells
As previously shown (Pendino et al., 2003; Pendino et al.,
2001), differentiation of NB4-LR1 APL cells (induced by the
combination of ATRA and 8-(4-chlorophenylthio)adenosine
cyclic 3,5-monophosphate (8-CPT-cAMP) treatments at 1
M and 200 M, respectively) was associated with a decrease
in hTERT mRNA level measured by real-time quantitative
PCR (Fig. 1). Western blots were then performed using the
corresponding protein extracts from control or differentiated
NB4-LR1 cells and two commercially available anti-hTERT
antibodies [(RCK-hTERT (Rockland) versus NCL-hTERT
(Novocastra)]. In extracts from untreated cells, RCK-hTERT
antibody revealed, among others, a band at 120 kDa, a
molecular weight expected for hTERT protein. The intensity
of labelling of this protein band is highly reduced during cell
differentiation, concomitant with the decrease of hTERT
mRNA level. NCL-hTERT antibody, one of the most
frequently used (according to the literature) tested here in the
same conditions on the same cell extracts, revealed a unique
protein band within the 100 kDa area. Note, however, that, as
previously shown on RCK-hTERT blots for the 120 kDa band,
this 100 kDa protein band was no longer detected in
differentiated NB4-LR1 cells. These large differences in
migration velocity prompted us to re-evaluate the efficacy and
Fig. 1. hTERT is downregulated during NB4-LR1 differentiation.
Differentiation (+) of NB4-LR1 cells was obtained by a 72-hour
treatment with the combination of ATRA (1 M) and 8-CPT-cAMP
(200 M). RNA and protein extracts were prepared as described in
the Materials and Methods. hTERT mRNA expression was quantified
by fluorescence real-time RT-PCR using the LightCycler®
technology and the LightCycler TeloTAGGG hTERT Kit from Roche
Diagnostics (Meylan, France). The hTERT level was normalized to
the expression of the housekeeping gene porphobilinogen deaminase
(PBGD) and expressed as a percentage of that detected in the
untreated cells. Western blot analyses were performed using RCK-
hTERT and NCL-hTERT antibodies. Positions of the molecular
weight markers are indicated on the left. Note that the low molecular
weight band on NCL-hTERT blot was not reproducibly detected.
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specificity of some commercially available anti-hTERT
antibodies and compare them with RCK-hTERT and NCL-
hTERT.
Immunodetection of hTERT in cell lines using
commercial antibodies
NCL-hTERT detection of a single protein band
irrelevant to hTERT by its SDS-PAGE migration
velocity
The properties and specific recognition domains on hTERT
protein by the various commercial antibodies used in this study
are shown in Table 1 and Fig. S1 in supplementary material.
HA-tagged hTERT and non-tagged hTERT-expressing HeLa
cells and anti-HA antibodies were used as migration controls
to precisely determine the position of the hTERT protein band
detected on western blots using the various anti-hTERT
antibodies. When lysates prepared from HA-tagged hTERT-
expressing HeLa cells were analyzed by sodium dodecyl
sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) and
immunoblotting, anti-HA antibodies recognized a protein with
a molecular weight of ~120 kDa as expected for the hTERT
protein (Fig. 2A, lane 2 and Fig. S3 in supplementary material).
No protein band was detected in extracts prepared from cells
transfected either with p-Babe empty vector (Fig. 2, lane 1) or
with non-tagged hTERT (supplementary material Fig. S3).
Numerous non-specific bands were generally seen in
immunoblotting experiments using various anti-hTERT
antibodies, except for NCL-hTERT antibody (Fig. 2A, lanes 3
and 4). Note that in this study we make a point of showing the
blots in full, in order to visualize both the specific and the non-
Table 1. Anti-hTERT antibodies used in the study
Supplier Reference Immunogen Location* Nature Dilution†
Novocastra NCL-hTERT aa: 173-320 N-terminal domain Mouse monoclonal 1:800
(clone 44F12)
Calbiochem 581400 (Calb-hTERT) aa: 568-581 Central domain Rabbit polyclonal 1:1000
Rockland 600-401-252 aa:1104-1123 C-terminal domain Rabbit polyclonal 1:1000
(RCK-hTERT)
Santa-Cruz TERT(L-20) sc-7214 (SC-hTERT) aa: 1092-1111 C-terminal domain Goat polyclonal 1:1000
Novus Biologicals NB 100-137 (NB-hTERT) Full recombinant protein Mouse monoclonal 1:1500
(clone 2C4)
*For details see supplementary material Fig. S1; †dilution used in immunoblot experiments; aa, amino acid.
Fig. 2. Comparative study for the
detection of hTERT protein in HeLa
cells by immunoblotting and
immunoprecipitation using
commercially available antibodies.
(A) Western blot analysis of total cell
lysates from HeLa cells transfected
with either HA-tagged hTERT (pB-
hTERT-HA) or p-Babe empty vector
alone (pB) using an anti-HA antibody
and various anti-hTERT antibodies.
(B) Immunoprecipitation (IP) of
lysates from HeLa cells transfected
with HA-tagged hTERT (pB-hTERT-
HA), the non-tagged hTERT protein
(pB-hTERT), or p-Babe empty vector
alone (pB) with anti-HA antibody
and immunoblotting with either anti-
HA antibody or various anti-hTERT
antibodies as indicated. Positions of
the molecular weight markers are
indicated on the left. Positions of the
proteins of interest are indicated by
arrows. Position of the heavy chain
(Ig) of the anti-HA antibody is
shown.
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specific bands. Among others, both Calb-hTERT and RCK-
hTERT antibodies recognized a protein that migrated in the
area of the expected molecular weight for hTERT (~120 kDa),
although at a different velocity (Fig. 2A, lanes 11, 12 and 7, 8,
13, 14, respectively). In contrast, and as previously noticed
(Lantuejoul et al., 2004) a clear and unique protein band was
observed on immunoblots using NCL-hTERT antibody (Fig.
2A, lanes 3 and 4). However, as previously shown (Fig. 1), this
protein migrated within a band with an apparent molecular
weight lower than expected for hTERT. Furthermore, this
antibody failed to recognize hTERT in hTERT-HA
immunoprecipitates (Fig. 2B, lane 5). Note that among all the
anti-hTERT antibodies used in this study, only RCK-hTERT
antibody was able to recognize the hTERT-HA fusion protein
in HA-immunoprecipitates (Fig. 2B, lane 8). No protein was
detected by either anti-HA antibody or RCK-hTERT antibody
in HA-immunoprecipitates from cells transfected by non-
tagged hTERT (Fig. 2B, lanes 3, 9 and 12) or p-Babe vector
alone (Fig. 2B, lanes 1, 7 and 10), confirming the specificity
of recognition of these antibodies.
These distinct patterns of recognition were also observed
when RCK-hTERT and NCL-hTERT antibodies were used to
label blots from NB4-LR1/hTERT extracts (Fig. 3A). Note that
RCK-hTERT antibody detected a protein band that migrated at
the same velocity as the protein recognized by NCL-hTERT.
Although it is possible that these proteins are identical, the
nature of this protein band remained to be elucidated.
NCL-hTERT detection of a single protein band in the
GM847 telomerase-negative cells
In extracts from the GM847 cell line, RCK-hTERT antibody
detected a faint protein band in the 120 kDa area, as expected
for this ALT cell line type found to be negative for telomerase
activity (Fig. 3B, left panel). In contrast, in the hTERT over-
expressing GM847, the same antibody detected a clear band at
120 kDa, likely to be hTERT. As an additional surprise, NCL-
hTERT antibody detected a single band in GM847 cells, at the
same 100 kDa molecular weight as in HeLa and NB4-LR1 cell
variants, and no label was found at ~120 kDa in the hTERT-
expressing GM847 cells (Fig. 3B, right panel).
Two distinct protein entities are recognized in a single
molecular complex by cross-immunoprecipitation
By co-immunoprecipitation experiments, we found that NCL-
hTERT antibody recognized the single 100 kDa protein band
in RCK-hTERT immunoprecipitates (Fig. 4A, lane 3) and
conversely, in a reverse immunoprecipitation experiment,
RCK-hTERT antibody recognized the 120 kDa hTERT protein
band in NCL-hTERT immunoprecipitates (Fig. 4B, lane 1).
Note that this antibody also recognized a ~100 kDa band in
NB4-LR1 whole extract (see in Fig. 3A).
Altogether these results demonstrate that the band detected
on western blots by NCL-hTERT antibody is most likely not
the expected hTERT protein but a protein entity associated with
hTERT since it co-immunoprecipitates with a protein which
was further detected as being hTERT on western blot using
RCK-hTERT. As NCL-hTERT antibody is so far, among the
commercially available antibodies, one of the most reported in
the literature for correlation studies between hTERT mRNA
level or telomerase activity and for quantitative evaluation of
the protein, we were eager to identify the actual protein
detected by this antibody and to know whether it was related
to telomerase.
Protein identification by mass spectrometry after
immunoprecipitation with RCK-hTERT and NCL-hTERT
antibodies
Separate immunoprecipitations from NB4-LR1/hTERT cell
lysates using either RCK-hTERT or NCL-hTERT antibodies
Journal of Cell Science 119 (13)
Fig. 3. Detection of hTERT protein in NB4-LR1/hTERT
(A) and GM847 cell extracts (B) using NCL-hTERT or
RCK-hTERT antibodies. Western blot analyses of total cell
lysates from NB4-LR1/hTERT (A) and from GM847 (B)
cells transfected with either hTERT (GM-pB-hTERT) or
pBabe empty vector alone (GM-pB). Positions of the
molecular weight markers are indicated on the left.
Positions of the proteins of interest are indicated by arrows.
Fig. 4. Immunoprecipitations of lysates from NB4-LR1/hTERT cells
with RCK-hTERT (A) or NCL-hTERT (B) antibodies and
immunoblotting with both antibodies. Positions of the molecular
weight markers are indicated on the left. Positions of the proteins of
interest are indicated by arrows. Position of the heavy chain (Ig) of
the NCL-hTERT antibody is shown. IgG, control for nonspecific
binding by performing immunoprecipitation reaction using normal
IgG. No immunoprecipitation was observed with control IgG.
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were performed. Immunoprecipitated materials were then
separated by SDS-PAGE and proteins visualized by Coomassie
Blue G-250 staining. Protein bands in the region of interest
(at 100 kDa for NCL-hTERT and RCK-hTERT
immunoprecipitates and at 120 kDa for RCK-hTERT
immunoprecipitates) were cut and subjected to mass
spectrometry (see Materials and Methods). The protein
identification data are summarized in Table 2.
RCK-hTERT immunoprecipitates contained a protein at the
expected molecular weight (120 kDa) identified as hTERT by
mass spectrometry. This result validates, without any
ambiguity, the hTERT specificity of this antibody. Heat shock
protein (Hsp)90 and nucleolin were  identified in two protein
bands of lower molecular weights (90 and 100 kDa,
respectively). This observation is in agreement with earlier
reports (Forsythe et al., 2001; Holt et al., 1999; Khurts et al.,
2004) indicating that these two proteins belong to the
telomerase complex. We further confirmed the presence of
these two proteins (Hsp90 and nucleolin) in the telomerase
complex by co-immunoprecipitation experiments on NB4-
LR1/hTERT extracts and immunoblotting using RCK-hTERT,
Hsp90 and nucleolin antibodies, respectively (Fig. S4A in
supplementary material).
Two proteins, nucleolin and alpha-actinin, were identified by
mass spectrometry analysis as components of the 100 kDa
band immunoprecipitated by the NCL-hTERT antibody.
Intriguingly, no band was identified as an hTERT-related
protein.
Co-immunoprecipitation experiments using extracts from
NB4-LR1/hTERT, followed by western blot analysis using
NCL-hTERT, RCK-hTERT, anti-nucleolin and anti-alpha-
actinin antibodies were performed. Nucleolin was found in
NCL-hTERT immunoprecipitates (Fig. 5, lane 1). A reverse
immunoprecipitation carried out with anti-nucleolin as the
precipitating antibody, pulled down a protein recognized
by NCL-hTERT that migrates at the same molecular weight
(100 kDa) as nucleolin (Fig. 5, compare lane 5 with 7).
Similarly, alpha-actinin was found in both NCL-hTERT and
nucleolin immunoprecipitates (Fig. S4B in supplementary
material).
Altogether these results suggest that nucleolin or alpha-
actinin are directly or indirectly immunoprecipitated by NCL-
hTERT. Of note, the fact that mass spectrometry failed to
identify any hTERT peptides in immunoprecipitates performed
with NCL-hTERT antibody supports the hypothesis that this
antibody does not recognize any related or truncated hTERT
protein.
Two-dimensional gel electrophoresis (2-DGE) shows
that NCL-hTERT recognizes nucleolin
Cell extracts from NB4-LR1 cells were subjected to two-
dimensional gel electrophoresis (2-DGE) and western blots
were developed with NCL-hTERT, anti-nucleolin and anti-
alpha-actinin antibodies (Fig. 6). Using anti-nucleolin
antibody, immunoreactive spots were detected at isoelectric
point (pI) 5.5-6.1, characteristic for nucleolin and its isoforms.
The nature of the spots detected at pI 4.5-4.8 has not yet been
identified. Surprisingly, using NCL-hTERT, no
immunoreactive protein spot was detected in the pI range 9.0-
9.6 that has been predicted for telomerase (data not shown).
However, it recognized spots of about 100 kDa ranging from
pI 4.5-4.8 and pI 5.5-6.0 that precisely corresponded to those
recognized by anti-nucleolin antibody. Interestingly, in the
Table 2. Identification of the proteins following data
searching with Mascot software (http://matrixscience.com)
Immunoprecipitating Protein band 
antibody* (kDa) Identification
RCK-hTERT 120 Human telomerase catalytic subunit
(600-401-252) 100 Heat shock protein Hsp90
100 Nucleolin
NCL-hTERT 100 Nucleolin
(clone 44F12) 100 Alpha-actinin-1 and -4
*Immunoprecipitates prepared from NB4-LR1 cell extracts using the
indicated antibody were fractionated by SDS-PAGE. The stained protein
bands of interest were cut from the gel in the corresponding region of interest
deduced from immunoblotting analysis, and subjected to mass spectrometry
(see Materials and Methods).
Fig. 5. Immunoprecipitations of lysates from NB4-LR1/hTERT cells
with NCL-hTERT or nucleolin antibodies and immunoblotting with
both antibodies. Positions of the molecular weight markers are
indicated on the left. Positions of the proteins of interest are
indicated by arrows. Position of the heavy chain (Ig) of antibodies is
shown. IgG, control for nonspecific binding by performing
immunoprecipitation reaction using normal mouse or rabbit IgG.
Fig. 6. Identification of nucleolin and alpha actinin in NB4-LR1 cells
by two dimensional electrophoresis and immunoblotting. NB4-LR1
proteins separated by isoelectric focusing in a pH 3-10 Bio-Rad IPG
gel in the first dimension and by electrophoresis in an SDS 10%
polyacrylamide gel in the second dimension. The proteins were
blotted onto PVDF membranes and revealed using the indicated
antibodies. Positions of the molecular weight marker are indicated on
the left. IP, isoelectric point.
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same experiment, the two-dimensional blot analysed with anti-
alpha-actinin antibody shows a clearly different pattern.
Although alpha-actinin migrates at the same molecular weight
as nucleolin, its pI is clearly different (4.96). Altogether, these
findings demonstrate that NCL-hTERT does not recognize
telomerase but nucleolin on western blots.
Immunofluorescence experiments show that RCK-
hTERT and NCL-hTERT recognize distinct structures.
As the above experiments relied only on western blot analyses,
immunofluorescence experiments were performed in order to
support the above results. These experiments were performed
on both NB4-LR1 cells, expressing a high level of endogenous
hTERT, and on GM847 cells used as a negative control for
hTERT expression.
In NB4-LR1 cells, endogenous hTERT detected by RCK-
hTERT is clearly observed throughout the cells, indicating that
it exists in both the nucleus and cytoplasm (Fig. 7A,B). It is
clear from confocal images that RCK-hTERT and NCL-
hTERT do not recognize the same protein even though some
co-localization in nucleolar structures exists (Fig. 7A,f and
B,f). This observation is not surprising, as it was previously
demonstrated that hTERT is present in the nucleolus (Yang et
al., 2002). The distribution of the protein recognized by NCL-
hTERT is similar to that of nucleolin (Fig. 7A,l).
In the GM847 cell line, the detection of hTERT by RCK-
hTERT was rather faint (Fig. 7C,a) supporting the results
obtained in western blot experiments. By contrast, NCL-
hTERT labelled the same structures as in NB4-LR1 cells, with
the same intensity (Fig. 7C,b). Therefore, using a different
experimental approach, these results corroborate the findings
previously achieved.
Journal of Cell Science 119 (13)
Fig. 7. Immunofluorescence and confocal microscopy. (A) hTERT was detected in NB4-LR1 cells using RCK-hTERT (red; Alexa Fluor 594-
conjugated anti-rabbit antibody). Nucleolin was detected either by MBL-nucleolin (green; Alexa Fluor 488-conjugated anti-mouse antibody) or
by SC-nucleolin (red; Alexa Fluor 594-conjugated anti-rabbit antibody). NCL-hTERT antibody detected a protein (green; Alexa Fluor 488-
conjugated anti-mouse antibody) that colocalized with nucleolin. Nuclei are stained in blue with DAPI. Panels f and l show the superimposition
of RCK-hTERT, NCL-hTERT, DAPI signals and SC-nucleolin, NCL-hTERT and DAPI signals, respectively. (B) Higher magnification of two
NB4-LR1 cells stained using either RCK-hTERT (b) or NCL-hTERT (d). Panels c, e and f are superimposed images of DAPI and RCK-hTERT
or NCL-hTERT signals and RCK-hTERT and NCL-hTERT signals, respectively. (C) Staining of GM847 cells using either RCK-hTERT (red;
Alexa Fluor 594-conjugated anti-rabbit antibody) or NCL-hTERT (green; Alexa Fluor 488-conjugated anti-mouse antibody) antibodies. Nuclei
are stained blue with DAPI. Bars, 10 m.
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Nucleolin is downregulated during differentiation and
cleaved during apoptosis of NB4-LR1 cells
We have shown (Fig. 1) that the level of the protein detected
by NCL-hTERT antibody decreased during differentiation of
NB4-LR1 cells concomitantly with the decrease of hTERT
mRNA. To further address the functional relevance of the
above results, we investigated whether nucleolin was similarly
regulated during differentiation. Fig. 8A clearly shows that,
like the protein detected by NCL-hTERT antibody, nucleolin
protein is reduced in differentiated cells.
The proteolysis of nucleolin during apoptosis has been
reported earlier (Ikezoe et al., 2003; Liu et al., 2005). It
generates a discrete cleavage product of ~90 kDa (Brockstedt
et al., 1998; Mi et al., 2003; Pasternack et al., 1991; Sengupta
et al., 2004). Therefore, if NCL-hTERT recognizes nucleolin,
it would be expected to recognize these cleavage products.
NB4-LR1 cells were treated with Oridonin or Arsenic, two
apoptosis inducers. Fig. 8B shows that the protein detected by
NCL-hTERT is rapidly degradated with the same cleavage
pattern and kinetic as for nucleolin, generating proteolytic
fragments of 88-90 kDa.
Collectively, these results demonstrate that the protein
detected by NCL-hTERT is not hTERT but a protein endowed
with the biochemical and biological features of nucleolin.
Discussion
The results obtained using mass peptide spectrometry analysis
and confirmed by co-immunoprecipitation experiments and
two-dimensional gel electrophoresis force us to conclude that
among the commercially anti-hTERT antibodies used in this
study, only RCK-hTERT antibody (Rockland) is suitable for
hTERT protein detection.
Besides this, our work has confirmed physiologically
interesting protein interaction in the hTERT enzymatic
complex (hTERT, nucleolin, Hsp90) and revealed a new one
between nucleolin and alpha-actinin.
Importantly, we demonstrate here that the NCL-hTERT
antibody clearly does not recognize hTERT, but nucleolin or a
nucleolin-related protein. This can be concluded for the
following reasons. (1) On SDS-PAGE and 2-DGE
immunoblotting, NCL-hTERT recognizes a protein that shares
a number of properties with nucleolin (similar molecular
weight and isoelectric point, degradation during apoptosis into
similar fragments, downregulation during differentiation); (2)
this protein is detected in western blot and in
immunofluorescence experiments independently of the
expression of hTERT; (c) this protein band was then identified
as nucleolin by classical microsequencing.
Although the predicted molecular weight of nucleolin
according to its coding cDNA is 77 kDa (Srivastava et al.,
1989), when run on a SDS-PAGE gel, it demonstrates an
apparent weight of 100 kDa (Srivastava et al., 1989). This
discrepancy has been attributed to the highly acidic N-terminal
domain of this protein, which contains a high number of
negatively charged amino acids (Ginisty et al., 1999).
Nucleolin has four RNA binding domains in the central portion
of the molecule and a carboxy-terminal RGG domain that
binds RNA, as well as some proteins (reviewed in Bouvet et
al., 1998; Creancier et al., 1993). Of note, this protein has been
identified to interact with telomerase (Khurts et al., 2004)
through its RNA binding domain 4 and its carboxy-terminal
RGG domain. This binding also involves the telomerase RNA
subunit hTR. This interaction between nucleolin and hTERT
would be critical for the nucleolar localization of hTERT.
Nucleolin has also been found to bind to the human telomeric
DNA sequence d(TTAGGG)n (Ishikawa et al., 1993; Pollice et
al., 2000).
There are a number of reasons why the results obtained with
NCL-hTERT (Novocastra) antibody were not questioned
earlier. First, like telomerase, nucleolin is associated with many
of the processes that are dysfunctional in neoplastic cells.
Nucleolin expression is highly proliferation dependent in
human tumour cells and nucleolin was used in studies of
different cancer cell lines as a useful marker for cell
proliferation (Derenzini et al., 1995). Furthermore, high levels
of silver-staining nucleolar proteins (of which nucleolin is a
major component) predict a poor prognosis in many types of
cancer (Derenzini, 2000). In nondividing cells, nucleolin
autocatalyzes its own degradation, and is present at a very low
level (Sirri et al., 1995). Nucleolin is also regulated both at
transcriptional and post-translational levels during
development of somatic tissue (Bicknell et al., 2005).
Second, as for telomerase, we show that differentiation of
APL cells was accompanied by a downregulation of nucleolin
Fig. 8. Nucleolin protein in NB4-
LR1 cells after differentiation and
apoptosis. (A) Differentiation (+)
of NB4-LR1 cells was obtained by
a 72-hour treatment with a
combination of ATRA (1 M) and
8-CPT-cAMP (200 M). (B)
Apoptosis was induced either by a
24-hour treatment with oridonin (4
g/ml) or a 24-hour treatment
with As2O3 (5 M). Proteolytic
fragments are indicated.
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in agreement with recent results obtained in other cell models
(Murakami et al., 1991; Otake et al., 2005).
Third, telomerase and nucleolin share the same intracellular
distribution. Indeed like telomerase, nucleolin is not only found
in the nucleus but also in the cytoplasm, depending on the cell
type. Furthermore, in the nucleus both telomerase and
nucleolin can be mobilized between nucleoli and the
nucleoplasm depending on the state of the cell (Daniely and
Borowiec, 2000; Daniely et al., 2002; Khurts et al., 2004;
Wong et al., 2002). Given these observations, it is not
surprising, therefore, that the pattern of expression for
nucleolin and telomerase were found to be almost identical.
NCL-hTERT was claimed to be made against a fragment of
the protein corresponding to a part of the N-terminal domain
of hTERT (amino acids: 173-320). However, we were not able
to identify any amino-acid sequence similarity between the
two proteins that could have the immunological properties of
NCL-hTERT, and the question of this misrecognition remains
non-elucidated. Nevertheless, the identification of nucleolin as
the protein recognized by NCL-hTERT antibody should lead
to an urgent re-evaluation of the results obtained with this
antibody and that are already published (Brustmann, 2005;
Dalerba et al., 2005; Domont et al., 2005; Dutu et al., 2005;
Elkak et al., 2005; Falchetti et al., 2003; Fullen et al., 2005;
Gulmann et al., 2005; Kraemer et al., 2003; Lantuejoul et al.,
2005; Lantuejoul et al., 2004; Luzar et al., 2005a; Luzar et al.,
2005b; Maes et al., 2005; Sabah et al., 2004; Sato et al., 2004;
Smith et al., 2004; Uziel et al., 2005; Yan et al., 2004).
Far from being detrimental to published work, our finding
should renew interest after reconsideration of the conclusions
previously drawn. Because part of the studies that used NCL-
hTERT antibody were designed to validate hTERT expression
as a diagnostic and prognostic marker of cancer, our present
findings confirm that the expression pattern of nucleolin could
also be associated with clinicopathological characteristics or
prognosis of tumours. Undoubtedly, future pathological and
biomolecular investigations should now consider these new
features.
Materials and Methods
Reagents
All-trans retinoic acid (ATRA; dissolved in ethanol as stock solution at 10–3 M), 8-
(4-chlorophenylthio)adenosine cyclic 3,5-monophosphate (8-CPT-cAMP;
dissolved in RPMI 1640 at 10–2 M), and As2O3 were purchased from Sigma (St
Louis, MO). Oridonin, a gift from Dr Q. J. Tang (Shanghai Academy of Agricultural
Sciences) was dissolved in DMSO as stock solution at 10 mg/ml.   
Cell lines, generation of stable clones and cell culture
The retrovirally infected acute promyelocytic leukemia (APL) NB4-LR1/hTERT-
GFP cells (Pendino et al., 2001) expressing both hTERT protein and the green
fluorescent protein (GFP) reporter from the same transcript and the NB4-LR1/GFP
subline expressing only the GFP were cultured as described previously (Lanotte et
al., 1991; Pendino et al., 2003; Pendino et al., 2002) in RPMI1640 medium
supplemented with 10% fetal bovine serum (PAA Laboratories, Les Mureaux,
France), penicillin (50 IU/ml), streptomycin (50 g/ml), L-glutamine (2 mM) and
sodium bicarbonate (70 mg/l), and incubated at 37°C in a 5% CO2 atmosphere
(Binder Incubator).
The GM847 (SV40 immortalized human skin fibroblasts) cell line, a gift from
Dr Olivia Pereira-Smith (Baylor College of Medicine, Waco, TX) and HeLa cells
were cultured in DMEM medium (Invitrogen) supplemented with 10% fetal bovine
serum (PAA Laboratories), L-glutamine (2 mM) and penicillin (50 IU/ml),
streptomycin (50 g/ml), and incubated at 37°C in a 5% CO2 atmosphere (Binder
Incubator). pBabe-puro, pBABE-puro-hTERT and pBABE-puro-hTERTHA,
provided by Dr Weinberg (MIT, Cambridge, MA), were transfected in GM847 cells
(GM847-pBabe, GM847-pBabe-hTERT) and in HeLa cells (HeLa-pBabe, HeLa-
pBabe-hTERT and HeLa-pBabe-hTERTHA) at about 80% confluency using
Lipofectamine 2000 reagent (Invitrogen) according to the manufacturer’s
instructions. Forty eight hours after transfection, cells were selected continuously
in puromycin (1 g/ml). Stable clones were isolated.
Analysis of hTERT expression by Real-time PCR
Full-length hTERT mRNA expression was quantified by fluorescence real-time RT-
PCR using the LightCycler® technology and the LightCycler TeloTAGGG hTERT
Kit from Roche Diagnostics (Meylan, France) according to the manufacturer’s
instructions. The hTERT level was normalized to the expression of the housekeeping
gene porphobilinogen deaminase (PBGD).
Western blotting
Whole cell pellets (2106 cells) were washed twice with ice-cold PBS, resuspended
in PBS (v/v), lysed by addition of an equal volume of 2 SDS buffer [1 = 50 mM
Tris-base (pH 6.8), 2% SDS, 100 mM dithiothreitol and 10% glycerol], and boiled
for 5 minutes, then put on ice for 5 minutes and boiled for another 5 minutes.
Insoluble material was removed by centrifugation at 14,000 g for 5 minutes. The
proteins (10 g) were separated by SDS-PAGE using a 7% polyacrylamide gel and
transferred onto a nitrocellulose membrane. The membranes were then stained with
Ponceau S to ensure transfer and equal loading. When necessary, the membranes
were cut into segments to allow immunoblotting with different antibodies. After
blocking in Tris-buffered saline containing 3% nonfat-milk and 0.1% Tween 20
(TBS-T) for 2 hours at room temperature, the blots were incubated overnight at 4°C
in fresh blocking solution with an appropriate dilution of primary antibody. 
The sources, properties and dilutions of anti-hTERT antibodies are described in
Table 1 and in Fig. S1 in supplementary material. Anti-actin (rabbit polyclonal;
Sigma, MO; dilution 1:5000), anti-HA (mouse monoclonal, clone F7; Santa Cruz
Biotechnology, sc-7392; dilution 1:2000), anti-Hsp90 (rabbit polyclonal;
Chemicon, AB3468; dilution 1:1000), anti-nucleolin (mouse monoclonal, clone 4E-
2; MBL, MO19-3, dilution 1:1000 for western blotting and rabbit polyclonal, H-
250; Santa Cruz Biotechnology, sc-13057, for immunoprecipitation) and anti-alpha-
actinin (mouse monoclonal; Chemicon; dilution 1:150) antibodies were used. Blots
were washed three times for 5 minutes each in TBS-T and then incubated with a
1:5000 dilution of appropriate horseradish peroxidase-conjugated secondary
antibody for 2 hours at room temperature. Blots were again washed three times for
5 minutes each in TBS-T and then developed by enhanced chemiluminescence
(ECL, Perkin Elmer Life Sciences).
Immunoprecipitation
NB4-LR1/hTERT cells (2107) were lysed with 1.0 ml of RIPA buffer (10 mM
Tris-HCl pH 7.4, 150 mM NaCl, 0.5% NP-40, 1% Triton X-100 and 1 mM EDTA)
with protease inhibitors (Sigma, MO) for 30 minutes on ice and then centrifuged at
14,000 g for 10 minutes. The soluble part was subjected to a preclearing step in
which it was incubated with 50 l of protein G-Sepharose (4 Fast Flow, Amersham
Biosciences, Piscataway, NJ) for 1 hour at 4°C. The precleared cell extracts were
then incubated with the adequate first antibody overnight at 4°C. Protein G-
Sepharose beads (50 l of 50% slurry) were then added for 1 hour at 4°C with
gentle shaking and centrifuged. The immunoprecipitates were washed three times
in cold RIPA buffer containing protease inhibitors. They were then resuspended in
60 l 1 SDS buffer, boiled for 5 minutes and centrifuged for 1 minute at 100 g.
The supernatants were saved as immunoprecipitate samples, fractionated by SDS-
PAGE as described above. Immunoprecipitation reactions to control for nonspecific
binding were performed using normal IgG.
Protein identification by peptide mass spectrometry
Immunoprecipitates prepared as described above were fractionated by SDS-PAGE
in two 7% polyacrylamide gels run in the same conditions. One of the gels was used
for immunoblotting with either RCK-hTERT or NCL-hTERT antibodies, whereas
the other was stained with colloidal Coomassie Brilliant Blue G-250. In brief, the
gel was fixed for 1 hour in 20% methanol containing 1.3% O-phosphoric acid. Then,
Coomassie Brilliant Blue G-250 solution was added to a final concentration of 1%.
Staining was carried out overnight with shaking at room temperature on an orbital
rotator. The gel was washed with 1% acetic acid until all Coomassie particles are
removed. Stained protein bands of interest were cut from the gel in the
corresponding region of interest, deduced from immunoblotting analysis. The
resulting peptides were extracted and digested with trypsin. Peptide mass
spectrometry of the samples was performed by using matrix-assisted laser
desorption-ionisation/time-of-flight mass spectrometry (MALDI-TOF/MS). The
tryptic peptide masses obtained were searched in the National Center for
Biotechnology Information nonredundant database using Mascot software (Matrix
Science, London, UK).
Two-dimensional gel electrophoresis
NB4-LR1 cells (107) were collected by centrifugation at 300 g, washed twice in
ice-cold PBS and lysed in 1 ml of IEF buffer (7 M urea, 2 M thiourea, 4% Chaps,
0.24% Triton X-100, 0.48% Bio-Lyte 3/10 ampholyte and 2 mM
tributylphosphine) containing 1% protease inhibitor cocktail (Sigma P8340),
1.25 mM NaF and 0.2 mM sodium orthovanadate. The lysate was incubated at
room temperature for 20 minutes with gentle agitation and clarified by
Journal of Cell Science 119 (13)
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centrifugation at 35,500 g for 1 hour. Protein concentration was determined by
the Bradford assay. ReadyStrip Immobilized pH gradient (IPG) strips (17 cm,
pH 3-10, Bio-Rad) were rehydrated with 100 g protein extract diluted in 350
l IEF buffer. The first dimension electrophoresis was performed with Multiphor
II IEF system (Amersham Biosciences). Focusing was carried out at 20°C under
a current limit of 50 A/strip and achieved with a total of 55,000 V/hour. The
second dimension electrophoresis was performed using a standard vertical slab
gel electrophoresis (Protean II XL system, Bio-Rad). The strip previously
incubated in 1% DTT then in 3% iodoacetamide in equilibration buffer (50 mM
Tris-HCl pH 8.8, 6 M urea, 30% glycerol 2% SDS), for 15 minutes each, was
loaded on the top of a vertical 10% polyacryamide gel (1919 cm). SDS-PAGE
was carried out at 15 mA/gel, 15°C, in classical SDS/Tris/glycine running buffer
followed by immunoblotting.
Immunofluorescence and confocal microscopy
Cells (1106) were collected by centrifugation, washed twice with PBS, fixed in
2% paraformaldehyde in PBS for 10 minutes at room temperature. Fixed cells were
permeabilized by 0.1% Triton X-100 in PBS at room temperature for 8 minutes and
blocked with 2% bovine serum albumin (BSA) in PBS overnight at 4°C. After three
washes in blocking buffer (0.05% BSA in PBS), cells were incubated with primary
antibody (NCL-hTERT, 1:50; RCK-hTERT, 1:150; MBL-nucleolin or SC-nucleolin,
1:200) in blocking buffer overnight, washed twice in PBS and incubated with
secondary antibody (either Alexa Fluor 488-conjugated anti-mouse or Alexa Fluor
594-conjugated anti-rabbit both from Molecular Probes, Invitrogen) diluted 1:1000
in 2% BSA in PBS, for 1 hour at room temperature. Subsequently, cells were washed
three times in PBS and dropped on glass slides which were mounted in Vectashield
mounting medium with 4,6-diaminidine-2-phenylindole (DAPI, Vector
Laboratories) to counterstain nuclei. Immunofluorescent images were acquired with
the LSM software on a Zeiss LSM510 Meta laser scanning confocal microscope
(Carl Zeiss, Oberkochen, Germany) equipped with a Zeiss Axiovert 200M (plan
Apochromat 63 1.40 NA oil immersion objective).
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